Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax plus Zanubrutinib vs Zanubrutinib alone in treatment-naïve CLL (Phase II, China)
CTR20244530Phase 2Active
- Sponsor
- BeiGene
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sonrotoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by BeiGene. Started Apr 2025; status: active.
02
Drugs
sonrotoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on CTR20244530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244530.